抗PD-1/PD-L1免疫治疗生物标志物研究进展

doi:10.3760/cma.j.issn.1673-422X.2019.01.009

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (1): 40-44.doi: 10.3760/cma.j.issn.1673-422X.2019.01.009

抗PD-1/PD-L1免疫治疗生物标志物研究进展

王欢¹,蒋海萍¹,高源¹,徐农¹,俞雄飞²

¹浙江大学医学院附属第一医院肿瘤内科，杭州310000；²浙江大学医学院附属第一医院肿瘤外科，杭州310000

收稿日期:2018-12-04 出版日期:2019-01-08 发布日期:2019-04-03
通讯作者: 徐农 E-mail:nongxu@zju.edu.cn
基金资助:
国家卫生和计划生育委员会科研基金（KWJ-ZJ-1802）；浙江省自然科学基金（LY15H160026）

Research progress of anti PD-1/PD-L1 immunotherapy biomarkers

Wang Huan¹, Jiang Haiping¹, Gao yuan¹, Xu Nong¹, Yu Xiongfei²

¹Department of Medical Oncology, First Affiliated Hospital of Zhejiang University, Hangzhou 310000, China; ²Department of Surgical Oncology, First Affiliated Hospital of Zhejiang University, Hangzhou 310000, China

Received:2018-12-04 Online:2019-01-08 Published:2019-04-03
Contact: Xu Nong E-mail:nongxu@zju.edu.cn
Supported by:
Science Foundation of National Health and Family Planning Commission (KWJ-ZJ-1802); Natural Science Foundation of Zhejiang Province of China (LY15H160026)

摘要/Abstract

摘要： 抗程序性死亡蛋白-1和程序性死亡蛋白配体-1（PD-L1）免疫检查点抑制剂已在多种实体瘤取得明显疗效，但是单药治疗有效率不高。因此，探寻合适的疗效预测标志物、精准选择潜在获益人群成为目前研究的热点。研究表明，PD-L1表达、肿瘤突变负荷、错配修复基因缺陷等可能与免疫治疗的疗效相关，对这些标志物的深入分析和探索可能为临床筛选免疫检查点抑制剂获益人群提供依据。

关键词: 免疫疗法, 生物学标记, PD-1, PD-L1

Abstract: Immunological checkpoint inhibitors of antiprogrammed cell death-1 and programmed cell death ligand-1 (PD-L1) have already demonstrated remarkable clinical efficacy for solid tumors, however, the effectiveness of single drug therapy in immunotherapy is not very high. Therefore, exploring the appropriate therapeutic predictive biomarkers so as to accurately identify the potential patients suitable for this therapy has become a research hotspot. Studies have shown that biomarkers such as PD-L1, tumor mutation burden and mismatch repair deficiency may be related to the efficacy of immunotherapy. Indepth analysis and exploration of these markers may provide a basis for determining those patients who are more likely to benefit from checkpoint inhibitor.

Key words: Immunotherapy, Biological markers, PD-1, PD-L1

王欢,蒋海萍,高源,徐农,俞雄飞. 抗PD-1/PD-L1免疫治疗生物标志物研究进展[J]. 国际肿瘤学杂志, 2019, 46(1): 40-44.

Wang Huan, Jiang Haiping, Gao yuan, Xu Nong, Yu Xiongfei. Research progress of anti PD-1/PD-L1 immunotherapy biomarkers[J]. Journal of International Oncology, 2019, 46(1): 40-44.

参考文献

［1］王巧红, 吴霞. 抗PD1/PDL1免疫治疗：筛选患者的生物标记物研究进展［J］. 中国免疫学杂志, 2017, 33(3): 457-463. DOI: 10.3969/j.issn.1000484X.2017.03.031. ［2］ Reck M, RodríguezAbreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PDL1positive nonsmallcell lung cancer［J］. N Engl J Med, 2016, 375(19): 1823-1833. DOI: 10.1056/NEJMoa1606774. ［3］ Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced nonsmallcell lung cancer: twoyear outcomes from two randomized, openlabel, phase Ⅲ trials (CheckMate 017 and CheckMate 057)［J］. J Clin Oncol, 2017, 35(35): 3924-3933. DOI: 10.1200/jco.2017.74.3602. ［4］赵沙, 蒋涛, 周彩存. 抗PD1/PDL1免疫治疗疗效预测标志物在非小细胞肺癌中的研究进展［J］. 肿瘤, 2016, 36(7): 823-828. DOI: 10.3781/j.issn.1000-7431.2016.55.175. ［5］ Voong KR, Feliciano J, Becker D, et al. Beyond PDL1 testingemerging biomarkers for immunotherapy in nonsmall cell lung cancer［J］. Ann Transl Med, 2017, 5(18): 376. DOI: 10.21037/atm.2017.06.48. ［6］ Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next generation sequencing identifies markers of response to PD1 blockade［J］. Cancer Immunol Res, 2016, 4(11): 959-967. DOI: 10.1158/2326-6066.CIR-16-0143. ［7］ Kowanetz M, Zou W, Shames DS, et al. Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC［J］. Ann Oncol, 2016, 27 Suppl 6: vi15vi42. DOI: http://doi.org/10.1093/annonc/mdw363.25. ［8］ Peters S, Creelan B, Hellmann MD, et al. Impact of tumor mutation burden on the efficacy of firstline nivolumab in stage iv or recurrent nonsmall cell lung cancer: an exploratory analysis of CheckMate 026［J］. Cancer Res, 2017, 77(13 Suppl): CT082. DOI: 10.1158/15387445.AM2017CT082. ［9］朱涤潮, 张涛, 张明辉, 等. MMR/MSI在结直肠癌抗PD1/PDL1免疫检查点治疗中的作用［J］. 肿瘤学杂志, 2017, 23(10): 904-909. DOI: 10.11735/j.issn.1671170X.2017.10.B014. ［10］ Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFRmutated nonsmall cell lung cancer—a metaanalysis［J］. J Thorac Oncol, 2017, 12(2): 403-407. DOI: 10.1016/j.jtho.2016.10.007. ［11］ Chowell D, Morris LGT, Grigg CM, et al. Patient HLA class Ⅰ genotype influences cancer response to checkpoint blockade immunotherapy［J］. Science, 2018, 359(6375): 582-587. DOI: 10.1126/science.aao4572. ［12］ Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA4 blockade relies on the gut microbiota［J］. Science, 2015, 350(6264): 1079-1084. DOI: 10.1126/science.aad1329. ［13］王珊, 董丽儒, 任会强, 等. 肺腺癌中PD1、PDL1蛋白表达与KRAS基因突变状态的相关性分析［J］. 临床与实验病理学杂志, 2017, 33(7): 754-758. DOI: 10.13315/j.cnki.cjcep.2017.07.011. ［14］ Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated nonsmallcell lung cancer (POPLAR): a multicentre, openlabel, phase 2 randomised controlled trial［J］. Lancet, 2016, 387(10030): 1837-1846. DOI: 10.1016/S01406736(16)00587-0. ［15］ Hermitte F. Biomarkers immune monitoring technology primer: immunoscore colon［J］. J Immunother Cancer, 2016, 4: 57. DOI: 10.1186/s40425-016-0161-x. ［16］ Galon J, Mlecnik B, Marliot F, et al. Validation of the immunoscore (IM) as a prognostic marker in stage Ⅰ/Ⅱ/Ⅲ colon cancer: results of a worldwide consortiumbased analysis of 1,336 patients［J］. J Clin Oncol, 2016, 34 Suppl 15: 3500. DOI: 10.1200/JCO.2016.34.15_suppl.3500. ［17］ Donnem T, Hald SM, Paulsen EE, et al. Stromal CD8+ Tcell density—a promising supplement to TNM staging in nonsmall cell lung cancer［J］. Clin Cancer Res, 2015, 21(11): 2635-2643. DOI: 10.1158/10780432.CCR-14-1905. ［18］ Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance［J］. Nature, 2014, 515(7528): 568-571. DOI: 10.1038/nature13954. ［19］ Martens A, WistubaHamprecht K, Yuan J, et al. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab［J］. Clin Cancer Res, 2016, 22(19): 4848-4858. DOI: 10.1158/10780432.CCR-16-0249. ［20］ Olugbile S, Kiyotani K, Inoue H, et al. P3.02c058 indepth molecular characterization of T cell clonal expansion induced by antiPD1 therapy in NSCLC［J］. J Thorac Oncol 2017, 12 (1 Suppl): S1310-S1311. DOI: https://doi.org/10.1016/j.jtho.2016.11.1853. ［21］ Sanmamed MF, PerezGracia JL, Schalper KA, et al. Changes in serum interleukin8 (IL8) levels reflect and predict response to antiPD1 treatment in melanoma and nonsmallcell lung cancer patients［J］. Ann Oncol, 2017, 28(8): 19881995. DOI: 10.1093/annonc/mdx190. ［22］ Lou Y, Diao L, Cuentas ER, et al. Epithelialmesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma［J］. Clin Cancer Res, 2016, 22(14): 3630-3642. DOI: 10.1158/1078-0432.CCR-15-1434. ［23］ Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates antiPDL1 efficacy［J］. Science, 2015, 350(6264): 1084-1089. DOI: 10.1126/science.aac4255. ［24］ Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1based immunotherapy against epithelial tumors［J］. Science, 2018, 359(6371): 91-97. DOI: 10.1126/science.aan3706. ［25］ Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to antiPD-1 immunotherapy in melanoma patients［J］. Science, 2018, 359(6371): 97-103. DOI: 10.1126/science.aan4236. ［26］ Voong KR, Feliciano J, Becker D, et al. Beyond PD-L1 testingemerging biomarkers for immunotherapy in nonsmall cell lung cancer［J］. Ann Transl Med, 2017, 5(18): 376. DOI: 10.21037/atm.2017.06.48.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[3]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[4]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[5]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[8]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[9]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[10]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[11]	过慈良, 江春平, 吴俊华. 肠道菌群与肿瘤免疫治疗[J]. 国际肿瘤学杂志, 2023, 50(7): 432-436.
[12]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[13]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	顾安琴, 龙金华, 金风. 鼻咽癌免疫治疗的临床研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 299-303.
[15]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.

抗PD-1/PD-L1免疫治疗生物标志物研究进展

Research progress of anti PD-1/PD-L1 immunotherapy biomarkers

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价